Grifols, S.A. (GRFS) Receives Consensus Rating of “Hold” from Brokerages

Shares of Grifols, S.A. (NASDAQ:GRFS) have been given a consensus rating of “Hold” by the seven brokerages that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company.

A number of analysts recently weighed in on GRFS shares. BidaskClub cut shares of Grifols, from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. Zacks Investment Research cut shares of Grifols, from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Bank of America Corporation reaffirmed a “buy” rating on shares of Grifols, in a research report on Tuesday, July 4th.

A number of institutional investors have recently made changes to their positions in GRFS. Comerica Bank boosted its position in Grifols, by 1.0% during the 1st quarter. Comerica Bank now owns 18,817 shares of the biotechnology company’s stock worth $398,000 after purchasing an additional 185 shares during the period. Ameriprise Financial Inc. boosted its position in Grifols, by 16.1% during the 1st quarter. Ameriprise Financial Inc. now owns 13,277 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 1,839 shares during the period. Stifel Financial Corp boosted its position in Grifols, by 4.3% during the 1st quarter. Stifel Financial Corp now owns 11,630 shares of the biotechnology company’s stock worth $226,000 after purchasing an additional 476 shares during the period. Geode Capital Management LLC boosted its position in Grifols, by 49.3% during the 1st quarter. Geode Capital Management LLC now owns 103,591 shares of the biotechnology company’s stock worth $1,954,000 after purchasing an additional 34,193 shares during the period. Finally, Morgan Stanley boosted its position in Grifols, by 20.2% during the 1st quarter. Morgan Stanley now owns 886,926 shares of the biotechnology company’s stock worth $16,741,000 after purchasing an additional 149,118 shares during the period. 21.93% of the stock is owned by hedge funds and other institutional investors.

Grifols, (NASDAQ GRFS) traded up 3.85% on Friday, hitting $22.37. The stock had a trading volume of 809,887 shares. The company’s 50-day moving average price is $21.30 and its 200 day moving average price is $21.00. The firm has a market cap of $30.57 billion, a price-to-earnings ratio of 45.51 and a beta of 0.98. Grifols, has a one year low of $14.27 and a one year high of $22.83.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/10/30/grifols-s-a-grfs-receives-consensus-rating-of-hold-from-brokerages.html.

About Grifols,

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

What are top analysts saying about Grifols S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Grifols S.A. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit